Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04417166
Other study ID # IELSG50
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 11, 2022
Est. completion date December 2026

Study information

Verified date May 2023
Source International Extranodal Lymphoma Study Group (IELSG)
Contact Emanuele Zucca, MD
Phone +41 58 666
Email ielsg@ior.usi.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with complete remission, partial response and stable disease will continue with pembrolizumab maintenance up to 2 years. Patients will be followed up to 4 years from treatment start.


Description:

This is an interventional, phase II, open label, single arm, multicentric clinical trial to be conducted in China. The primary objective is to test the efficacy of concurrent RT-Pembrolizumab in patients with limited stage NK/T cell lymphoma and who are not eligible to receive chemotherapy. The secondary objectives are to further explore the efficacy and safety of a the combination of RT and Pembrolizumab as initial treatment of the patients population. All eligible patients will be treated with standard IFRT and concurrent pembrolizumab administered intravenously, over 30 minutes starting on day 1 of RT (C1D1, at the dose of 200 mg, every 3 weeks). After 6 cycles of pembrolizumab patients will undergo restaging imaging. Patients with complete remission (CR), partial response (PR) and stable disease (SD) will continue with pembrolizumab maintenance up to 2 years that will be administered intravenously, at the dose of 200 mg, over 30 minutes on day 1 every 3 weeks up to 34 cycles. The follow-up period will last up to 4 years from treatment start.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2026
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed histological diagnosis of NK/T Cell Lymphoma - No previous anti-lymphoma treatment - Age = 18 years - Ann Arbor stage I-II - At least one measurable/evaluable site after diagnostic biopsy before treatment start - At least one of the following high-risk features: age > 60 years, elevated LDH, stage II, primary tumor invasion - Patient ineligible to receive full dose standard chemotherapy - ECOG performance status of 0-1 - Signed Informed consent - Ability to comply with the protocol - Adequate hematological and organ function; - Tumor tissue (fresh preferred, archival tissue is also acceptable) - For women of childbearing potential a negative pregnancy test on day 1 of cycle 1 and agree to adopt an adequate measure to avoid pregnancy during study treatment and for at least one year from end of treatment - For men agreement to remain abstinent or to use barrier contraception Exclusion Criteria: - Advanced stage disease (AA stage III-IV) - Extranasal type NKTCL - History of autoimmune disease - History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer). - History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis - Active infection requiring systemic therapy - Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina. - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent - HBsAg, HCV or HIV positivity. Positive serology is admitted for HBV and HCV but DNA/RNA test must be negative - Administration of a live attenuated vaccine within 4 weeks before cyle 1 day 1. Patients must not receive live, attenuate vaccines, including influenza vaccines at any time during study. - Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed. - Evidence of suspect of CNS disease - Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound Pembrolizumab itself or to the excipients in its formulation). - Has had an allogenic tissue/solid organ transplant - Known history of active TB (Bacillus Tuberculosis)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
50 mg powder for concentrate for solution for infusion
Radiation:
Involved Field Radiation Therapy
50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age > 60 years, stage II, elevated serum LDH levels). Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed.

Locations

Country Name City State
China Shanghai Rui-Jin Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
International Extranodal Lymphoma Study Group (IELSG)

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) rate at 2 years - The proportion of patients without disease progression after 2 years from treatment start Response will be assessed using international criteria for response assessment in lymphomas (Cheson 2014) and their update for patients receiving checkpoint inhibitors (Cheson 2016 Lyric) 2 years from treatment start
Secondary Complete remission rate (CRR) - Proportion of patients with complete responses CRR defined according to Cheson 2014 criteria After 4 months from treatment start (End of Induction phase), Maintenance Phase:every 4 months during the first year and then every 6 months until end of treatment. Follow up: every 4 months during first year, then every 6 months during second year
Secondary 2-year Event-free survival - Proportion of patient without disease related events after 2 years from treatment start 2 years from treatment start
Secondary Treatment related mortality - Number of treatment related deaths From informed consent signature to 90 days after the last study treatment administration
Secondary 2-year Overall survival - Proportion of patients alive after 2 years from treatment start 2 years from treatment start
Secondary Rate of adverse events - Analysis of incidence, severity and relationship of adverse events Adverse Events severity will be classified according to the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V. 5.0 From Informed Consent signature to 30 days for AEs or 90 for SAEs after end of treatment
Secondary Overall Response Rate (ORR) - calculated as the sum of the complete and partial remission rates ORR defined according to Cheson 2014 criteria After 4 months from treatment start (End of Induction phase) Maintenance Phase: every 4 months during the first year and then every 6 months until end of treatment. Follow up: every 4 months during first year, then every 6 months during second year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Terminated NCT02359162 - Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Phase 3
Recruiting NCT02080234 - Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL Phase 2
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Not yet recruiting NCT03051555 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma N/A
Not yet recruiting NCT03051542 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma N/A
Recruiting NCT03154918 - GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma Phase 2
Recruiting NCT01933282 - MESA Treatment for NK/T Cell Lymphoma Phase 2
Terminated NCT02533323 - P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens Phase 2
Active, not recruiting NCT03439501 - Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] Phase 2
Recruiting NCT02859402 - Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Phase 2